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ABSTRACT 33 
Aims: Previous studies have identified candidate circulating microRNAs (circmiRs) as 34 
biomarkers for heart failure (HF) by relatively insensitive arrays, validated in small cohorts. 35 
We used RNA sequencing to identify novel candidate circmiRs and compared this to 36 
previously identified circmiRs in a large, prospective cohort of acute HF (AHF) patients.   37 
Methods and results: RNA sequencing of plasma from instrumented pigs was used to 38 
identify circmiRS produced by myocardium, and found production of known myomirs and 39 
microRNA(miR)-1306-5p. We next tested the prognostic value of this and 11 other circmiRs 40 
in a prospective cohort of 496 AHF patients, from whom blood samples were collected at 41 
several time points (max 7) during the study’s 1-year follow-up. The primary endpoint (PE) 42 
was the composite of all-cause mortality and HF rehospitalization. In the prospective AHF 43 
cohort, 188 patients reached the PE, and higher values of repeatedly measured miR-1306-44 
5p were positively associated with the risk of the PE at that same time-point 45 
(HR(95%CI):4.69(2.18–10.06)), independent of clinical characteristics and NT-proBNP. 46 
Baseline miR-1306-5p did not improve model discrimination/reclassification significantly 47 
compared to NT-proBNP. For miR-320a, miR-378a-5p, miR-423-5p and miR-1254 48 
associations with the PE were present after adjustment for age and sex 49 
(HRs(95%CI):1.38(1.12–1.70), 1.35(1.04–1.74), 1.45(1.10–1.92),1.22(1.00–1.50), 50 
respectively). Detection rate of myomiRs miR208a-3p and miR499a-5p was very low.  51 
Conclusion: Repeatedly-measured miR-1306-5p was positively associated with adverse 52 
clinical outcome in AHF, even after multivariable adjustment including NT-proBNP. Yet, 53 
baseline miR-1306-5p did not add significant discriminatory value to NT-proBNP. Low-54 
abundant, heart-enriched myomiRs are often undetectable which mandates more sensitive 55 
assays.  56 
 57 
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INTRODUCTION 60 
To date, natriuretic peptides are the only circulating biomarkers which are routinely used for 61 
diagnosis and prognostication of heart failure (HF).1 Improved HF prognostication may 62 
identify patients that could benefit from closer follow-up and from more aggressive treatment. 63 
Therefore, exploration of novel prognostic markers of HF can improve clinical management. 64 
Circulating microRNAs (circmiRs) have been proposed as an attractive new class of 65 
biomarkers because of their stability in the circulation, and their ensuing reliable assessment 66 
in easily accessible samples.2 However, most published studies to date involve relatively 67 
small numbers of HF patients with most often discrepant findings between separate 68 
studies.3-7 Larger studies are scarce and have not investigated the temporal patterns of 69 
microRNAs (miRs) in patients with HF.8 Importantly, longitudinal circmiR measurements in 70 
HF patients may provide further insight into individual, temporal patterns and the patient’s 71 
ensuing risk of disease progression and adverse outcome.  72 
 In the present study, we used an RNA sequencing discovery experiment in pigs to 73 
identify circmiRs produced by the myocardium. Subsequently, we tested the potential for 74 
prognostication of the most promising novel circmiR (miR-1306-5p) in a set of 475 patients 75 
who were prospectively included for serial sampling after an AHF admission and compared it 76 
to multiple miRs known to be cardiac-enriched or already previously linked to HF (miR-1254, 77 
miR-22-3p, miR-345-5p, miR-378a-3p, miR-423-5p, miR-320a,  miR-133a-3p, miR-133b, 78 
miR-499a-5p, miR-622, and miR-208a-3p).  79 
 80 
81 
 4 
METHODS 82 
 83 
Part I: Preclinical study design 84 
 85 
Aortic Banding and plasma and tissue harvesting  86 
Experiments were performed in Aortic Banding (AoB)-treated (n=29) and sham-operated 87 
(n=21) Yorkshire x Landrace swine (see Supplemental Material for details, including surgical 88 
procedures and sacrifice of the animals). Briefly, following thoracotomy, the proximal 89 
ascending aorta was dissected free and, in AoB animals a band was placed.9 Up to eight 90 
weeks later, swine were instrumented for simultaneous arterial and coronary venous blood 91 
sampling, followed by excision of the heart and harvesting of myocardial tissue samples from 92 
the left ventricular anterior wall.  93 
 94 
RNA Sequencing 95 
RNA was isolated from myocardial tissue and from arterial and coronary venous plasma 96 
samples of AoB-treated (n=4) and sham-operated (n=4) swine at 8 weeks follow-up after 97 
sham and AoB. For subsequent sequencing, RNA was pooled from myocardial tissue 98 
samples and from plasma obtained from arterial and coronary venous samples from AoB-99 
treated and sham-operated samples, respectively. Pooled RNA from each sample was then 100 
divided into two, to have 2 technical replicates per sample. This resulted in a total of 16 101 
samples, which were sent to BGI Shenzhen (China) for sequencing of small RNAs. At the 102 
BGI, libraries were prepared using the NEBNext® Multiplex Small RNA Library Prep Set for 103 
Illumina® kit. Samples were sequenced on an Illumina NextSeq 500 platform and base-104 
calling was performed using the bcl2fastq 2.0 Conversion Software from Illumina. 105 
Quality control of fastq files was performed using FASTQC 106 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/). Trimmomatic version 0.32 was used 107 
to carry out 3´ adapter clipping of reads, using a phred score cut-off of 30 in order to trim low 108 
quality bases whilst ensuring that reads with a length below 18 bases were discarded.10 109 
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Differential miR expression analysis 110 
We analyzed differential expression  in the RNA sequencing data using the R Bioconductor 111 
package, DESeq2.11 MiRs were selected based on next-generation sequencing results. Only 112 
miRs that were differentially expressed or had a high abundance in heart tissue were 113 
analyzed. We used quantitative polymerase chain reaction (PCR) to analyze expression 114 
levels of selected miRs in coronary venous and arterial plasma samples from 21 sham pigs 115 
and 29 AoB pigs. Plasma samples were analyzed to obtain a trans-coronary gradient in a 116 
comparable fashion; sham arterial plasma vs. coronary venous plasma, and AoB arterial 117 
plasma vs. coronary venous plasma. Owing to the availability of replicates, the dispersion 118 
method “pooled” from DESeq2 was used to accurately estimate dispersion between each 119 
comparison. DESeq2's negative binomial model was used to estimate differentially 120 
expressed miRs for each analysis. At the end, only those miRs passing a fold-change (log2) 121 
cut-off of 1.0 together with a False Discovery Rate cut-off of 0.05 were deemed significantly 122 
differentially expressed. 123 
 124 
Part II: Clinical study design 125 
TRIUMPH was an observational, prospective study enrolling patients admitted with acute HF 126 
in 14 hospitals in The Netherlands, between September 2009 and December 2013. The 127 
study was designed to allow analysis of novel potential biomarkers for prognostication of HF 128 
patients, with a particular interest directed towards changes in blood-biomarker patterns over 129 
time and their value for prognostication in HF patients. The study was approved by the 130 
medical ethics committee at all participating centers. All patients provided written informed 131 
consent. 132 
 133 
134 
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Patients 135 
Patients were eligible if ≥18 years old and hospitalized for acute HF, resulting from 136 
decompensation of known, chronic HF or newly diagnosed HF, and all three of the following 137 
criteria were met: (1) natriuretic peptide levels elevated to ≥3 times the upper limit of normal 138 
(determined in each individual hospital); (2) evidence of sustained left ventricular 139 
dysfunction, defined as moderate to poor systolic function or grade II (pseudonormal) to 140 
grade IV (fixed restrictive) diastolic dysfunction on echocardiography during hospitalization; 141 
and (3) treatment with intravenous diuretics. Patients were excluded in case they suffered 142 
from HF precipitated by a non-cardiac condition, by an acute ST-segment elevation 143 
myocardial infarction or by severe valvular dysfunction without sustained left ventricular 144 
dysfunction. Furthermore, patients were excluded if they were scheduled for coronary 145 
revascularization, listed for heart transplantation, suffered from severe renal failure for which 146 
dialyses was needed, or had a coexistent condition with a life expectancy <1 year.  147 
 148 
Patient management 149 
Patient management was at the discretion of the treating clinician, in accordance with the 150 
guidelines of the European Society of Cardiology.12 Of note, biomarker data obtained in the 151 
context of this study were unknown to the treating physicians and thus were not used for 152 
clinical decisions. 153 
 154 
Study procedures 155 
Blood samples were obtained from all patients during hospitalization at admission (day 1), 156 
once during days 2 to 4 and subsequently at discharge; thus, 3 samples per patient were 157 
drawn during hospitalization. Additionally, blood samples were obtained at outpatient clinic 158 
follow-up visits, planned 2 to 4 weeks, 3 months, 6 months, and 9 to 12 months after 159 
discharge; thus, 4 samples were drawn during follow-up. As such, a total of 7 samples were 160 
obtained for each patient, unless a patient was censored or died before all samples could be 161 
taken. A short medical evaluation was performed and blood samples were collected at every 162 
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follow-up visit. Adverse cardiovascular events and changes in medication were recorded in 163 
electronic case report forms. 164 
 165 
MiR- and NT-proBNP measurements 166 
MiRNAs were measured in all separate plasma samples as described in detail in the 167 
Supplemental Material. MiR-1254, miR-22-3p, 423-5p, miR-320a and miR-622 were 168 
selected because they were associated with HF in previous studies,5,7,13 miR-378a-3p and 169 
miR-345-5p because of their enrichment in cardiomyocytes,14 and miR133a-3p, miR133b, 170 
miR208a-3p and miR499a-5p are muscle specific miRs (so-called ‘myomiRs’), of which the 171 
latter two are heart specific and are released during myocardial injury.15,16 MiR486-5p was 172 
used for normalization of the other miRs, because endogenous miRs have been shown to 173 
carry advantages for normalization compared to spike-in (e.g. Cel39) or small RNAs.17 In the 174 
RNA-sequencing experiment we noticed that miR486-5p is exceptionally abundant 175 
(representing the vast majority of all detected miRs in the circulation, see Results below) and 176 
stable compared to other miRs, making it a suitable candidate to use as a normalizer (details 177 
of normalization are described in the Supplementary Material NT-proBNP measurements are 178 
also described in the Supplemental Material. 179 
 180 
Quality control of human miR measurements 181 
PCR of circulating miRs is sensitive to false or inaccurate signals, which may result in 182 
missing values.18 Missing values may result from technical errors, but are most often due to 183 
template levels that are too low to measure reliably with qPCR. Therefore, we used a quality 184 
assessment algorithm to ensure the validity of each measurement. This algorithm is 185 
described more extensively elsewhere.19 In brief, we distinguished three groups of 186 
measurements: ‘detectable’, ‘non-detectable’ (signal too low) and ‘invalid’. If the 187 
measurement passed all the quality checks, it was considered valid and was marked 188 
‘detectable’. In case of a ‘non-detectable’ signal, the measurement was set to a low value, 189 
which was based on the PCR experiment parameters. If the measurement did not pass the 190 
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quality controls of the algorithm, it was defined as ‘invalid’. Such measurements were not 191 
used in further analyses.   192 
 193 
Endpoints 194 
The primary endpoint comprised the composite of all-cause mortality and readmission for 195 
HF. The latter was defined as an unplanned rehospitalization due to acute HF, with at least 196 
two of the following three criteria: (1) elevated natriuretic peptide levels ≥3 times the upper 197 
limit of normal, (2) symptoms of cardiac decompensation (e.g. rales, edema or elevated 198 
central venous pressure), and (3) administration of intravenous diuretics. Secondary 199 
endpoints included the individual components of the primary endpoint and additionally 200 
cardiovascular mortality. 201 
During follow-up, information on vital status and hospital readmissions was obtained 202 
until at least 9 months with a maximum of 400 days after the index hospital admission. We 203 
approached the civil registry, screened all medical records, and asked patients for 204 
information during their follow-up visits.  A clinical event committee blinded to the biomarker 205 
results subsequently reviewed all collected information and adjudicated primary and 206 
secondary endpoints.  207 
 208 
Statistical analysis 209 
The associations between the baseline miR measurements and the risk of a study 210 
endpoint were assessed using Cox proportional hazards models. Abundant miRs were 211 
examined as continuous variables, while low-abundance miRs were entered into the models 212 
as dichotomous variables (detectable versus non-detectable, as defined by the algorithm 213 
described above), For repeated miR measurements, associations between the current level 214 
of each separate miR at a particular time point and the risk of an endpoint at that same time 215 
point were assessed using a joint modeling approach, which combines a linear mixed-effects 216 
model for the repeated miR measurements with a Cox proportional hazards model for the 217 
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risk of experiencing the event of interest.20 A detailed description of the statistical analysis is 218 
provided in the Supplemental Material. 219 
 220 
RESULTS 221 
RNA sequencing in pigs samples 222 
Post-quality control, the total number of reads per sample successfully aligned to pig-specific 223 
hairpin sequences ranged from 83.7 to 97.3 %. Combining all reads together, followed by 224 
discarding sequences longer than 25 nucleotides and those with low abundance (< 4 reads 225 
per sample) resulted in 373 x 106 reads that were successfully mapped to pig hairpin 226 
sequences. Aligning unmapped reads to hairpin sequences of other species increased the 227 
alignment rate by a negligible fraction (0.46%), suggesting that known hairpin sequences of 228 
Sus Scrofa were close to complete. We therefore, only used those sequences that were 229 
mapped to Sus scrofa hairpins.  230 
Whilst calculating the number of reads aligned to each hairpin and mature miR 231 
sequence, a high abundance of miR-486-5p was observed in plasma samples (constituting 232 
92.5-97% of all reads). There were a number of circmirs with a positive and significant trans-233 
coronary gradient (figure 1). Among these were also known myomirs like miR-133a. In 234 
addition, less known circmirs like miR-1306 also showed a positive gradient. A comparison 235 
of next-generation sequencing based miR expression across tissue samples revealed a total 236 
of 16 miRs differentially expressed in sham-operated tissue compared to AoB-treated tissue 237 
(Table 1) among which miR-1306-5p was also significantly upregulated. 238 
Given the positive trans-coronary gradient of miR-1306-5p and its significant 239 
upregulation in myocardial tissue of AoB compared to Sham pigs, we further evaluated the 240 
potential role of miR-1306-5p as a circulating biomarker. We compared the values obtained 241 
for miR-1306 in the control samples that are routinely taken along on the qPCR plates with 242 
the measurement of the HF samples, which showed that levels of circulating miR-1306-5p 243 
were significantly higher in the HF patients OR [95%CI] = 1.43 (1.033 – 1.98) in arbitrary 244 
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unit)/ln(pg/ml), p<0.05), further increasing the probability that circulating miR-1306-5p could 245 
serve as a novel biomarker for HF. 246 
 247 
Prospective Clinical study: Baseline characteristics  248 
A total of 496 patients were enrolled in the TRIUMPH clinical cohort and provided written 249 
informed consent. Three patients withdrew their informed consent. Eighteen patients were 250 
withdrawn from statistical analyses due to inclusion violation. These patients had no 251 
evidence of sustained systolic or diastolic left ventricular dysfunction on echocardiography. 252 
Accordingly, 475 patients compose the analysis set. Median age was 74 years (interquartile 253 
range (IQR) 65-80), 63% were men and median left ventricular ejection fraction was 30% 254 
(IQR 21-42) (Table 2). Median baseline NT-proBNP level was 4135 pg/mL (IQR 2123–255 
9328). 256 
 257 
Clinical endpoints  258 
The composite primary endpoint was reached by 188 patients (40%) during a median follow-259 
up of 325 (IQR 85–401) days. A total of 113 patients died, of which 77 were confirmed to die 260 
from a cardiovascular cause, and 123 patients were re-hospitalized for decompensated HF.  261 
 262 
Circulating miR measurements 263 
A total of 2214 blood samples were available for the current investigation. Median (IQR) 264 
number of miR measurements per patient was 3 (IQR 2–5). Supplemental table 1 displays 265 
the number of measurements that were detectable per miR. MiRs that were detectable in 266 
less than 700 out of 2214 samples were not used as continuous variables in further analyses 267 
but were dichotomized (detectable vs. non-detectable) as described above. MiRs that were 268 
examined as continuous variables were: miR-320a, miR-1254, miR-22-3p, miR-378a-3p, 269 
miR-423-5p, miR-345-5p and miR-1306-5p. MiRs that were dichotomized were: miR-133a-270 
3p, miR-133b, and miR-499a-5p. MiR-486-5p was used for normalization of these miR 271 
levels. MiR-622 and miR-208a-3p were only detectable in 56 and 6 out of 2214 samples, 272 
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respectively. This low expression did not allow for meaningful statistical analysis of these 273 
miRs. Additionally, supplemental table 2 shows the baseline characteristics stratified by 274 
invalid versus valid measurement of baseline miR-1306-5p. 275 
 Finally, miR expression levels in patients with HF with reduced ejection fraction 276 
(HFrEF) vs. HF with preserved ejection fraction (HFpEF) are presented in supplemental 277 
table 3. 278 
 279 
Associations between baseline miR levels and clinical endpoints 280 
Figure 2 shows the difference in the risk of experiencing the primary endpoint for patients in 281 
different quartiles of baseline miR1306-5p levels (p< 0.001). This was confirmed in the 282 
subsequently fitted Cox models, where baseline miR1306-5p levels were significantly and 283 
independently associated with the primary endpoint (hazard ratios (HRs)(95%CI)): 284 
1.13(1.03-1.23) (Table 3). From the other known miRs, only the baseline levels of miR-320a 285 
were significantly and independently associated with the primary endpoint (HRs(95%CI): 286 
1.10(1.00-1.21)). Associations with secondary endpoints are shown in Supplemental Table 287 
4. A sensitivity analysis on the subgroup of HFrEF patients, rendered a HR for baseline 288 
miR1306-5p in relation to the primary endpoint that was similar to the HR in the total group, 289 
but with a wider CI ((HR(95%CI): 1.09(0.95–1.25) (supplemental table 5). This was most 290 
likely caused by a decrease in statistical power in this subgroup.  291 
 292 
Associations between temporal miR patterns and clinical endpoints 293 
Repeatedly measured miR1306-5p level was positively and independently associated with 294 
the primary endpoint (HR(95%CI): (4.69(2.18–10.06)), p< 0.001 (Table 4). The temporal 295 
patterns of miR-320a, miR-378a-3p and miR-423-5p were positively associated with the 296 
primary endpoint after adjustment for age and sex. However, these associations 297 
disappeared after multivariable adjustment. The temporal pattern of miR-1254 displayed a 298 
borderline significant association with the primary endpoint after adjustment for age and sex 299 
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(HR(95%CI): 1.22(1.00-1.50). Associations of temporal patterns with secondary endpoints 300 
are shown in Supplemental Table 6. 301 
 302 
Incremental prognostic value of miR-1306-5p 303 
Adding miR-1306-5p to a model containing NT-proBNP age, sex, systolic blood pressure, 304 
diabetes mellitus, atrial fibrillation, BMI, previous hospitalization for HF during the last 6 305 
months, ischemic HF, and baseline eGFR, we found a change in C-statistic of 0.012 (95%CI: 306 
-0.006–0.029), a continuous net reclassification (cNRI) improvement of 0.125(-0.016–0.267), 307 
and an integrated discrimination index (IDI) improvement of 0.020(-0.013–0.053), as shown 308 
in supplemental table 7. Thus, the incremental prognostic value of miR1306-5p on top of NT-309 
proBNP did not reach statistical significance. 310 
 13 
DISCUSSION 311 
Direct RNA sequencing of plasma from instrumented pigs revealed a number of circmiRs to 312 
be produced by the pig myocardium, including miR-1306-5p which had not yet been 313 
identified as a miR related to the heart. Subsequently, we found in a prospective AHF cohort 314 
that repeatedly-assessed circulating miR-1306-5p is positively and independently associated 315 
with all-cause mortality and HF hospitalization. This association was independent of NT-316 
proBNP. However, a model containing baseline miR-1306-5p measurements did not 317 
significantly improve model discrimination or reclassification when compared to NT-proBNP. 318 
Repeatedly-assessed circulating miR-320a, miR-378a-3p, miR-423-5p and miR-1254 were 319 
associated with the primary endpoint after adjustment for age and sex (albeit borderline for 320 
miR-1254), but not after further multivariable adjustment for clinical characteristics. 321 
Furthermore, an independent association was found between baseline values of miR-1306-322 
5p and miR-320a and the primary endpoint.  323 
Importantly, our findings are in line with those described in a manuscript where two 324 
large cohorts have been studied (Bayes-Genis et al, submitted back-to-back). In those two 325 
independent cohorts, miR-1306-5p was also positively and significantly associated with the 326 
risk of all-cause mortality or HF hospitalization. This further strengthens our findings and for 327 
the first time we see reproducible results on circulating miRs across three large cohorts. This 328 
contrasts with previous studies where usually one, mostly smaller cohort was analyzed,21 329 
and results have most often been discrepant between separate studies. To the best of our 330 
knowledge, the association between miR-1306-5p and cardiovascular disease has not been 331 
previously investigated in other studies, and further research is warranted on its expected 332 
targets. 333 
 RNA sequencing using plasma-derived RNA led to the discovery of miR-1306-5p 334 
produced by the heart. Akat et al also used RNA sequencing to analyze miRs potentially 335 
produced by the human heart.22 However, their study was not designed to assess the clinical 336 
value of circmiRs as biomarkers. A word of caution concerns the large proportion of invalid 337 
and undetectable miR-1306-5p measurements which reduces power and illustrates the need 338 
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for more sensitive methods of miR assessment to enable optimal use of this marker for 339 
clinical prognostication. Nevertheless, the current study carried sufficient statistical power to 340 
demonstrate a significant association between repeatedly measured miR-1306-5p and the 341 
primary and secondary endpoints in spite of the proportion of invalid and undetectable 342 
measurements. 343 
 In line with our results, the study by Bayes-Genis et al. also found an association 344 
between miR-1254 and clinical outcome. Other existing data on miR-1254 are limited; of 345 
note is that Tijsen et al demonstrated upregulation of miR-1254 in HF cases compared to 346 
healthy controls.5 An association between higher baseline miR423-5p levels and signs of 347 
progressive HF has been demonstrated in animal models,6 and human studies with limited 348 
sample size.3,5 Rising miR423-5p has also been related to worsening left ventricular function 349 
and has been shown to be upregulated in non-ST elevation myocardial infarction patients.23 350 
Our results agree with the findings of the aforementioned studies. Conversely, in recent a 351 
study in 236 acute HF patients, an inverse association was observed between miR423-5p 352 
and hospital readmission.8 However, this finding could not be reproduced in the validation 353 
cohort which was examined.8 Smaller studies have previously demonstrated higher 354 
circulating levels of miR-320a in HF patients compared to healthy individuals.7,24 In addition, 355 
rat models have proven that overexpression of miR-320a leads to a greater loss of 356 
cardiomyocytes during infarction and that inhibition of miR-320a leads to reduced infarction 357 
size.25 Furthermore, miR-320a showed a protective effect on left ventricular remodeling after 358 
myocardial ischemia-reperfusion injury in a rat model.26 The results of the current study are 359 
in line with these previous studies, and further expand the evidence concerning miR-320a by 360 
showing that baseline measurements are independently associated with adverse prognosis 361 
in patients with HF, and that repetitively-measured miR-320a is independently associated 362 
with heart failure hospitalization in particular. The temporal pattern of miR-378a-3p was also 363 
associated with the primary endpoint. Naga Prasad et al showed downregulation of miR-364 
378a-3p in left ventricular free wall tissue of HF patients with dilated cardiomyopathy.4 In 365 
contrast, in the current study we examined circulating levels of miR-378a-3p. In addition, 366 
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Weber et al found higher levels of circulating miR-378a-3p in 5 patients with coronary artery 367 
disease, compared to 5 healthy controls.27 However, studies other than ours on the 368 
prognostic value of miR-378a-3p in patients with HF are lacking.  369 
Repeatedly measured, highly-abundant miRs only showed age-and sex-adjusted 370 
significant associations with the primary endpoint, and associations disappeared after 371 
multivariable adjustment. Possibly, prognostic information of these circmiRs, which are 372 
probably not produced by the heart, can be easily diluted.  Conversely, myomiRs, i.e. miRs 373 
which are skeletal- and cardiac-muscle specific, carry potential to provide prognostic 374 
information that is incremental to clinical characteristics. Such myomiRs play a central role in 375 
myogenesis regulation and muscle remodeling.28,29 Although the main sources of circulating 376 
myomiRs, and in particular the relationship between myomiRs in tissue and plasma have yet 377 
to be fully elucidated, an association between cardiac damage (caused by myocardial 378 
infarction or  myocarditis) and upregulation of circulating myomiRs  has been previously 379 
demonstrated.15 Moreover, circulating myomiR levels have been associated with skeletal 380 
muscle wasting.30 We examined several myomiRs in the current investigation (miR133a-3p, 381 
miR133b, miR208a-3p and miR499a-5p). However, myomiRs are lowly expressed in the 382 
circulation, as illustrated by the fact that they were non-detectable in a large proportion of the 383 
samples available in our study. Thus, we were forced to perform a simplified analysis and 384 
examined the association between presence of detectable myomiR levels at baseline and 385 
occurrence adverse events. The loss of information inherent to such an analysis may have 386 
obscured potential associations with the outcome. Therefore, more sensitive assays are 387 
needed to properly examine the roles of myomiRs in HF.  388 
To remove noise by less robust QPCR results we designed and implemented a strict 389 
and conservative algorithm to remove unreliable QPCR data, and at the same time retain 390 
reliable assessment of ‘too low to detect’ signals.  Furthermore, we used miR486-5p to 391 
normalize our data, as using such endogenous miRs for this purpose has been shown to 392 
carry advantages.17 We have separately described our quality control algorithm we used 393 
here (provided for review purposes) and given the strong concordance between three large 394 
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cohorts we have thus measured strengthens the point of view that such algorithms help to 395 
remove noise and improve reproducibility.  396 
Some aspects of this study warrant consideration. First, aortic banding has been 397 
used to model heart failure. This is a model that shows strong similarity to the TAC model in 398 
mice and has previously been used in multiple studies as a model for pressure-overload 399 
hypertrophy.31-34 This model may not be fully representative of human left ventricular 400 
dysfunction. However, our observation that miR 1306-5p, identified in our swine model, does 401 
provide prognostic potential in the clinic, underscores the validity of our approach. Second, 402 
we did not adjust our analyses for multiple comparisons, because the miRs we examined 403 
were not selected in a hypothesis-free manner but had resulted from previous fundamental 404 
and clinical studies. Nevertheless, if we applied Bonferroni correction, the results would 405 
remain statistically significant. The association between repeated miR1306-5p and the 406 
primary endpoint rendered a HR(95%CI) of 4.69(2.18–10.06) and a p-value < 0.0001; since 407 
we examined 7 repeatedly measured miRs, the Bonferroni threshold for the p-value would 408 
be 0.05/7=0.007. Furthermore, we focused on patients with known heart failure. Studies 409 
using a healthy control group may provide insights into temporal miR patterns in healthy 410 
persons. 411 
In conclusion, in patients hospitalized for AHF, baseline and repeatedly-assessed 412 
miR-1306-5p was independently associated with adverse clinical outcome. Associations of 413 
temporal patterns of miR-320a, miR-378a-5p, miR-423-5p and miR-1254 with adverse 414 
clinical outcome were not independent of clinical characteristics. Myocyte-specific miRs were 415 
non-detectable in a large proportion of the samples. More sensitive myomiR assays are 416 
needed in order to precisely estimate the risk associated with elevated levels of miRs such 417 
as miR1306-5p, and to investigate whether cardiac specific myomiRs on their part are 418 
capable of providing additional information to established, clinical risk predictors.  419 
420 
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Figure titles and legends 555 
 556 
Figure 1: Trans-coronary gradients in plasma microRNAs. 557 
The number indicates the number of pigs (out of a total of 44 pigs) with both a detectable 558 
venous and arterial microRNA value. The gradient is calculated as arterial minus venous Ct 559 
value of the microRNA, and shown as Mean±SEM. A negative value indicates release of the 560 
microRNA by the myocardium, and a positive value indicates uptake. The p-value is 561 
calculated using a paired samples T-test, and indicates the difference between arterial and 562 
venous Ct value of the microRNA. 563 
 564 
Figure 2: Kaplan-Meier survival curves for the primary endpoint of death or readmission for 565 
HF in the four quartiles of baseline miR-1306-5p levels. 566 
Q1 lowest quartile, Q4 highest quartile. 567 
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ABSTRACT 33 
Aims: Previous studies have identified candidate circulating microRNAs (circmiRs) as 34 
biomarkers for heart failure (HF) by relatively insensitive arrays, validated in small cohorts. 35 
We used RNA sequencing to identify novel candidate circmiRs and compared this to 36 
previously identified circmiRs in a large, prospective cohort of acute HF (AHF) patients.   37 
Methods and results: RNA sequencing of plasma from instrumented pigs was used to 38 
identify circmiRS produced by myocardium, and found production of known myomirs and 39 
microRNA(miR)-1306-5p. We next tested the prognostic value of this and 11 other circmiRs 40 
in a prospective cohort of 496 AHF patients, from whom blood samples were collected at 41 
several time points (max 7) during the study’s 1-year follow-up. The primary endpoint (PE) 42 
was the composite of all-cause mortality and HF rehospitalization. In the prospective AHF 43 
cohort, 188 patients reached the primary endpointPE, and higher values of repeatedly 44 
measured miR-1306-5p were positively associated with the risk of the primary endpointPE at 45 
that same time-point (HR(95%CI):4.69(2.18–10.06)), independent of clinical characteristics 46 
and NT-proBNP. Baseline miR-1306-5p did not improve model discrimination/reclassification 47 
significantly compared to NT-proBNP. For miR-320a, miR-378a-5p, miR-423-5p and miR-48 
1254 associations with the PE were present after adjustment for age and sex 49 
(HRs(95%CI):1.38(1.12–1.70), 1.35(1.04–1.74), 1.45(1.10–1.92),1.22(1.00–1.50), 50 
respectively). Detection rate of myomiRs miR208a-3p and miR499a-5p was very low.  51 
Conclusion: MiR-1306-5p is produced by the myocardium and higher levels of rRepeatedly-52 
measured miR-1306-5p was positively associated with adverse clinical outcome in AHF, 53 
even after multivariable adjustment including NT-proBNP. Yet, baseline miR-1306-5p did not 54 
add significant discriminatory value to NT-proBNP.provide prognostic information beyond 55 
NT-proBNP. Low-abundant, heart-enriched myomiRs are often undetectable which 56 
mandates more sensitive assays.  57 
 58 
Key words: MicroRNA, Biomarkers, Heart Failure, Prognosis, Serial Measurements. 59 
60 
 3 
INTRODUCTION 61 
To date, natriuretic peptides are the only circulating biomarkers which are routinely used for 62 
diagnosis and prognostication of heart failure (HF).1 Improved HF prognostication may 63 
identify patients that could benefit from closer follow-up and from more aggressive treatment. 64 
Therefore, exploration of novel prognostic markers of HF can improve clinical management. 65 
Circulating microRNAs (circmiRs) have been proposed as an attractive new class of 66 
biomarkers because of their stability in the circulation, and their ensuing reliable assessment 67 
in easily accessible samples.2 However, most published studies to date involve relatively 68 
small numbers of HF patients with most often discrepant findings between separate 69 
studies.3-7 Larger studies are scarce and have not investigated the temporal patterns of 70 
microRNAs (miRs) in patients with HF.8 Importantly, longitudinal circmiR measurements in 71 
HF patients may provide further insight into individual, temporal patterns and the patient’s 72 
ensuing risk of disease progression and adverse outcome.  73 
 In the present study, we used an RNA sequencing discovery experiment in pigs to 74 
identify circmiRs produced by the myocardium. Subsequently, we tested the potential for 75 
prognostication of the most promising novel circmiR (miR-1306-5p) in a set of 475 patients 76 
who were prospectively included for serial sampling after an AHF admission and compared it 77 
to multiple miRs known to be cardiac-enriched or already previously linked to HF (miR-1254, 78 
miR-22-3p, miR-345-5p, miR-378a-3p, miR-423-5p, miR-320a,  miR-133a-3p, miR-133b, 79 
miR-499a-5p, miR-622, and miR-208a-3p).  80 
 81 
82 
 4 
METHODS 83 
 84 
Part I: Preclinical study design 85 
 86 
Aortic Banding and plasma and tissue harvesting  87 
Experiments were performed in Aortic Banding (AoB)-treated (n=29) and sham-operated 88 
(n=21) Yorkshire x Landrace swine (see Supplemental Material for details, including surgical 89 
procedures and sacrifice of the animals). Briefly, following thoracotomy, the proximal 90 
ascending aorta was dissected free and, in AoB animals a band was placed.9 Up to eight 91 
weeks later, swine were instrumented for simultaneous arterial and coronary venous blood 92 
sampling, followed by excision of the heart and harvesting of myocardial tissue samples from 93 
the left ventricular anterior wall.  94 
 95 
RNA Sequencing 96 
RNA was isolated from myocardial tissue and from arterial and coronary venous plasma 97 
samples of AoB-treated (n=4) and sham-operated (n=4) swine at 8 weeks follow-up after 98 
sham and AoB. For subsequent sequencing, RNA was pooled from myocardial tissue 99 
samples and from plasma obtained from arterial and coronary venous samples from AoB-100 
treated and sham-operated samples, respectively. Pooled RNA from each sample was then 101 
divided into two, to have 2 technical replicates per sample. This resulted in a total of 16 102 
samples, which were sent to BGI Shenzhen (China) for sequencing of small RNAs. At the 103 
BGI, libraries were prepared using the NEBNext® Multiplex Small RNA Library Prep Set for 104 
Illumina® kit. Samples were sequenced on an Illumina NextSeq 500 platform and base-105 
calling was performed using the bcl2fastq 2.0 Conversion Software from Illumina. 106 
Quality control of fastq files was performed using FASTQC 107 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/). Trimmomatic version 0.32 was used 108 
to carry out 3´ adapter clipping of reads, using a phred score cut-off of 30 in order to trim low 109 
quality bases whilst ensuring that reads with a length below 18 bases were discarded.10 110 
 5 
Differential miR expression analysis 111 
We analyzed differential expression  in the RNA sequencing data using the R Bioconductor 112 
package, DESeq2.11 MiRs were selected based on next-generation sequencing results. Only 113 
miRs that were differentially expressed or had a high abundance in heart tissue were 114 
analyzed. We used quantitative polymerase chain reaction (PCR) to analyze expression 115 
levels of selected miRs in coronary venous and arterial plasma samples from 21 sham pigs 116 
and 29 AoB pigs. Plasma samples were analyzed to obtain a trans-coronary gradient in a 117 
comparable fashion; sham arterial plasma vs. coronary venous plasma, and AoB arterial 118 
plasma vs. coronary venous plasma. Owing to the availability of replicates, the dispersion 119 
method “pooled” from DESeq2 was used to accurately estimate dispersion between each 120 
comparison. DESeq2's negative binomial model was used to estimate differentially 121 
expressed miRs for each analysis. At the end, only those miRs passing a fold-change (log2) 122 
cut-off of 1.0 together with a False Discovery Rate cut-off of 0.05 were deemed significantly 123 
differentially expressed. 124 
 125 
Part II: Clinical study design 126 
TRIUMPH was an observational, prospective study enrolling patients admitted with acute HF 127 
in 14 hospitals in The Netherlands, between September 2009 and December 2013. The 128 
study was designed to allow analysis of novel potential biomarkers for prognostication of HF 129 
patients, with a particular interest directed towards changes in blood-biomarker patterns over 130 
time and their value for prognostication in HF patients. The study was approved by the 131 
medical ethics committee at all participating centers. All patients provided written informed 132 
consent. 133 
 134 
135 
 6 
Patients 136 
Patients were eligible if ≥18 years old and hospitalized for acute HF, resulting from 137 
decompensation of known, chronic HF or newly diagnosed HF, and all three of the following 138 
criteria were met: (1) natriuretic peptide levels elevated to ≥3 times the upper limit of normal 139 
(determined in each individual hospital); (2) evidence of sustained left ventricular 140 
dysfunction, defined as moderate to poor systolic function or grade II (pseudonormal) to 141 
grade IV (fixed restrictive) diastolic dysfunction on echocardiography during hospitalization; 142 
and (3) treatment with intravenous diuretics. Patients were excluded in case they suffered 143 
from HF precipitated by a non-cardiac condition, by an acute ST-segment elevation 144 
myocardial infarction or by severe valvular dysfunction without sustained left ventricular 145 
dysfunction. Furthermore, patients were excluded if they were scheduled for coronary 146 
revascularization, listed for heart transplantation, suffered from severe renal failure for which 147 
dialyses was needed, or had a coexistent condition with a life expectancy <1 year.  148 
 149 
Patient management 150 
Patient management was at the discretion of the treating clinician, in accordance with the 151 
guidelines of the European Society of Cardiology.12 Of note, biomarker data obtained in the 152 
context of this study were unknown to the treating physicians and thus were not used for 153 
clinical decisions. 154 
 155 
Study procedures 156 
Blood samples were obtained from all patients during hospitalization at admission (day 1), 157 
once during days 2 to 4 and subsequently at discharge; thus, 3 samples per patient were 158 
drawn during hospitalization. Additionally, blood samples were obtained at outpatient clinic 159 
follow-up visits, planned 2 to 4 weeks, 3 months, 6 months, and 9 to 12 months after 160 
discharge; thus, 4 samples were drawn during follow-up. As such, a total of 7 samples were 161 
obtained for each patient, unless a patient was censored or died before all samples could be 162 
taken. A short medical evaluation was performed and blood samples were collected at every 163 
 7 
follow-up visit. Adverse cardiovascular events and changes in medication were recorded in 164 
electronic case report forms. 165 
 166 
MiR- and NT-proBNP measurements 167 
MiRNAs were measured in all separate plasma samples as described in detail in the 168 
Supplemental Material. MiR-1254, miR-22-3p, 423-5p, miR-320a and miR-622 were 169 
selected because they were associated with HF in previous studies,5,7,13 miR-378a-3p and 170 
miR-345-5p because of their enrichment in cardiomyocytes,14 and miR133a-3p, miR133b, 171 
miR208a-3p and miR499a-5p are muscle specific miRs (so-called ‘myomiRs’), of which the 172 
latter two are heart specific and are released during myocardial injury.15,16 MiR486-5p was 173 
used for normalization of the other miRs, because endogenous miRs have been shown to 174 
carry advantages for normalization compared to spike-in (e.g. Cel39) or small RNAs.17 In the 175 
RNA-sequencing experiment we noticed that miR486-5p is exceptionally abundant 176 
(representing the vast majority of all detected miRs in the circulation, see Results below) and 177 
stable compared to other miRs, making it a suitable candidate to use as a normalizer (details 178 
of normalization are described in the Supplementary Material NT-proBNP measurements are 179 
also described in the Supplemental Material. 180 
 181 
Quality control of human miR measurements 182 
PCR of circulating miRs is sensitive to false or inaccurate signals, which may result in 183 
missing values.18 Missing values may result from technical errors, but are most often due to 184 
template levels that are too low to measure reliably with qPCR. Therefore, we used a quality 185 
assessment algorithm to ensure the validity of each measurement. This algorithm is 186 
described more extensively elsewhere.19 In brief, we distinguished three groups of 187 
measurements: ‘detectable’, ‘non-detectable’ (signal too low) and ‘invalid’. If the 188 
measurement passed all the quality checks, it was considered valid and was marked 189 
‘detectable’. In case of a ‘non-detectable’ signal, the measurement was set to a low value, 190 
which was based on the PCR experiment parameters. If the measurement did not pass the 191 
 8 
quality controls of the algorithm, it was defined as ‘invalid’. Such measurements were not 192 
used in further analyses.   193 
 194 
Endpoints 195 
The primary endpoint comprised the composite of all-cause mortality and readmission for 196 
HF. The latter was defined as an unplanned rehospitalization due to acute HF, with at least 197 
two of the following three criteria: (1) elevated natriuretic peptide levels ≥3 times the upper 198 
limit of normal, (2) symptoms of cardiac decompensation (e.g. rales, edema or elevated 199 
central venous pressure), and (3) administration of intravenous diuretics. Secondary 200 
endpoints included the individual components of the primary endpoint and additionally 201 
cardiovascular mortality. 202 
During follow-up, information on vital status and hospital readmissions was obtained 203 
until at least 9 months with a maximum of 400 days after the index hospital admission. We 204 
approached the civil registry, screened all medical records, and asked patients for 205 
information during their follow-up visits.  A clinical event committee blinded to the biomarker 206 
results subsequently reviewed all collected information and adjudicated primary and 207 
secondary endpoints.  208 
 209 
Statistical analysis 210 
The associations between the baseline miR measurements and the risk of a study 211 
endpoint were assessed using Cox proportional hazards models. Abundant miRs were 212 
examined as continuous variables, while low-abundance miRs were entered into the models 213 
as dichotomous variables (detectable versus non-detectable, as defined by the algorithm 214 
described above), For repeated miR measurements, associations between the current level 215 
of each separate miR at a particular time point and the risk of an endpoint at that same time 216 
point were assessed using a joint modeling approach, which combines a linear mixed-effects 217 
model for the repeated miR measurements with a Cox proportional hazards model for the 218 
 9 
risk of experiencing the event of interest.20 A detailed description of the statistical analysis is 219 
provided in the Supplemental Material. 220 
 221 
RESULTS 222 
RNA sequencing in pigs samples 223 
Post-quality control, the total number of reads per sample successfully aligned to pig-specific 224 
hairpin sequences ranged from 83.7 to 97.3 %. Combining all reads together, followed by 225 
discarding sequences longer than 25 nucleotides and those with low abundance (< 4 reads 226 
per sample) resulted in 373 x 106 reads that were successfully mapped to pig hairpin 227 
sequences. Aligning unmapped reads to hairpin sequences of other species increased the 228 
alignment rate by a negligible fraction (0.46%), suggesting that known hairpin sequences of 229 
Sus Scrofa were close to complete. We therefore, only used those sequences that were 230 
mapped to Sus scrofa hairpins.  231 
Whilst calculating the number of reads aligned to each hairpin and mature miR 232 
sequence, a high abundance of miR-486-5p was observed in plasma samples (constituting 233 
92.5-97% of all reads). There were a number of circmirs with a positive and significant trans-234 
coronary gradient (figure 1). Among these were also known myomirs like miR-133a. In 235 
addition, less known circmirs like miR-1306 also showed a positive gradient. A comparison 236 
of next-generation sequencing based miR expression across tissue samples revealed a total 237 
of 16 miRs differentially expressed in sham-operated tissue compared to AoB-treated tissue 238 
(Table 1) among which miR-1306-5p was also significantly upregulated. 239 
Given the positive trans-coronary gradient of miR-1306-5p and its significant 240 
upregulation in myocardial tissue of AoB compared to Sham pigs, we further evaluated the 241 
potential role of miR-1306-5p as a circulating biomarker. We compared the values obtained 242 
for miR-1306 in the control samples that are routinely taken along on the qPCR plates with 243 
the measurement of the HF samples, which showed that levels of circulating miR-1306-5p 244 
were significantly higher in the HF patients OR [95%CI] = 1.43 (1.033 – 1.98) in arbitrary 245 
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unit)/ln(pg/ml), p<0.05), further increasing the probability that circulating miR-1306-5p could 246 
serve as a novel biomarker for HF. 247 
 248 
Prospective Clinical study: Baseline characteristics  249 
A total of 496 patients were enrolled in the TRIUMPH clinical cohort and provided written 250 
informed consent. Three patients withdrew their informed consent. Eighteen patients were 251 
withdrawn from statistical analyses due to inclusion violation. These patients had no 252 
evidence of sustained systolic or diastolic left ventricular dysfunction on echocardiography. 253 
Accordingly, 475 patients compose the analysis set. Median age was 74 years (interquartile 254 
range (IQR) 65-80), 63% were men and median left ventricular ejection fraction was 30% 255 
(IQR 21-42) (Table 2). Median baseline NT-proBNP level was 4135 pg/mL (IQR 2123–256 
9328). 257 
 258 
Clinical endpoints  259 
The composite primary endpoint was reached by 188 patients (40%) during a median follow-260 
up of 325 (IQR 85–401) days. A total of 113 patients died, of which 77 were confirmed to die 261 
from a cardiovascular cause, and 123 patients were re-hospitalized for decompensated HF.  262 
 263 
Circulating miR measurements 264 
A total of 2214 blood samples were available for the current investigation. Median (IQR) 265 
number of miR measurements per patient was 3 (IQR 2–5). Supplemental table 1 displays 266 
the number of measurements that were detectable per miR. MiRs that were detectable in 267 
less than 700 out of 2214 samples were not used as continuous variables in further analyses 268 
but were dichotomized (detectable vs. non-detectable) as described above. MiRs that were 269 
examined as continuous variables were: miR-320a, miR-1254, miR-22-3p, miR-378a-3p, 270 
miR-423-5p, miR-345-5p and miR-1306-5p. MiRs that were dichotomized were: miR-133a-271 
3p, miR-133b, and miR-499a-5p. MiR-486-5p was used for normalization of these miR 272 
levels. MiR-622 and miR-208a-3p were only detectable in 56 and 6 out of 2214 samples, 273 
 11 
respectively. This low expression did not allow for meaningful statistical analysis of these 274 
miRs. Additionally, supplemental table 2 shows the baseline characteristics stratified by 275 
invalid versus valid measurement of baseline miR-1306-5p. 276 
 Finally, miR expression levels in patients with HF with reduced ejection fraction 277 
(HFrEF) vs. HF with preserved ejection fraction (HFpEF) are presented in supplemental 278 
table 3. 279 
 280 
Associations between baseline miR levels and clinical endpoints 281 
Figure 2 shows the difference in the risk of experiencing the primary endpoint for patients in 282 
different quartiles of baseline miR1306-5p levels (p< 0.001). This was confirmed in the 283 
subsequently fitted Cox models, where baseline miR1306-5p levels were significantly and 284 
independently associated with the primary endpoint (hazard ratios (HRs)(95%CI)): 285 
1.13(1.03-1.23) (Table 3). From the other known miRs, only the baseline levels of miR-320a 286 
were significantly and independently associated with the primary endpoint (HRs(95%CI): 287 
1.10(1.00-1.21)). Associations with secondary endpoints are shown in Supplemental Table 288 
4. A sensitivity analysis on the subgroup of HFrEF patients, rendered a HR for baseline 289 
miR1306-5p in relation to the primary endpoint that was similar to the HR in the total group, 290 
but with a wider CI ((HR(95%CI): 1.09(0.95–1.25) (supplemental table 5). This was most 291 
likely caused by a decrease in statistical power in this subgroup.  292 
 293 
Associations between temporal miR patterns and clinical endpoints 294 
Repeatedly measured miR1306-5p level was positively and independently associated with 295 
the primary endpoint (HR(95%CI): (4.69(2.18–10.06)), p< 0.001 (Table 4). The temporal 296 
patterns of miR-320a, miR-378a-3p and miR-423-5p were positively associated with the 297 
primary endpoint after adjustment for age and sex. However, these associations 298 
disappeared after multivariable adjustment. The temporal pattern of miR-1254 displayed a 299 
borderline significant association with the primary endpoint after adjustment for age and sex 300 
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(HR(95%CI): 1.22(1.00-1.50). Associations of temporal patterns with secondary endpoints 301 
are shown in Supplemental Table 6. 302 
 303 
Incremental prognostic value of miR-1306-5p 304 
Adding miR-1306-5p to a model containing NT-proBNP age, sex, systolic blood pressure, 305 
diabetes mellitus, atrial fibrillation, BMI, previous hospitalization for HF during the last 6 306 
months, ischemic HF, and baseline eGFR, we found a change in C-statistic of 0.012 (95%CI: 307 
-0.006–0.029), a continuous net reclassification (cNRI) improvement of 0.125(-0.016–0.267), 308 
and an integrated discrimination index (IDI) improvement of 0.020(-0.013–0.053), as shown 309 
in supplemental table 7. Thus, the incremental prognostic value of miR1306-5p on top of NT-310 
proBNP did not reach statistical significance. 311 
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DISCUSSION 312 
Direct RNA sequencing of plasma from instrumented pigs revealed a number of circmiRs to 313 
be produced by the pig myocardium, including miR-1306-5p which had not yet been 314 
identified as a miR related to the heart. Subsequently, we found in a prospective AHF cohort 315 
that repeatedly-assessed circulating miR-1306-5p is positively and independently associated 316 
with all-cause mortality and HF hospitalization. This association was independent of NT-317 
proBNP. However, a model containing baseline miR-1306-5p measurements did not 318 
significantly improve model discrimination or reclassification when compared to NT-proBNP. 319 
Repeatedly-assessed circulating miR-320a, miR-378a-3p, miR-423-5p and miR-1254 were 320 
associated with the primary endpoint after adjustment for age and sex (albeit borderline for 321 
miR-1254), but not after further multivariable adjustment for clinical characteristics. 322 
Furthermore, an independent association was found between baseline values of miR-1306-323 
5p and miR-320a and the primary endpoint.  324 
Importantly, our findings are in line with those described in a manuscript where two 325 
large cohorts have been studied (Bayes-Genis et al, submitted back-to-back). In those two 326 
independent cohorts, miR-1306-5p was also positively and significantly associated with the 327 
risk of all-cause mortality or HF hospitalization. This further strengthens our findings and for 328 
the first time we see reproducible results on circulating miRs across three large cohorts. This 329 
contrasts with previous studies where usually one, mostly smaller cohort was analyzed,21 330 
and results have most often been discrepant between separate studies. To the best of our 331 
knowledge, the association between miR-1306-5p and cardiovascular disease has not been 332 
previously investigated in other studies, and further research is warranted on its expected 333 
targets. 334 
 RNA sequencing using plasma-derived RNA led to the discovery of miR-1306-5p 335 
produced by the heart. Akat et al also used RNA sequencing to analyze miRs potentially 336 
produced by the human heart.22 However, their study was not designed to assess the clinical 337 
value of circmiRs as biomarkers. A word of caution concerns the large proportion of invalid 338 
and undetectable miR-1306-5p measurements which reduces power and illustrates the need 339 
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for more sensitive methods of miR assessment to enable optimal use of this marker for 340 
clinical prognostication. Nevertheless, the current study carried sufficient statistical power to 341 
demonstrate a significant association between repeatedly measured miR-1306-5p and the 342 
primary and secondary endpoints in spite of the proportion of invalid and undetectable 343 
measurements. 344 
 In line with our results, the study by Bayes-Genis et al. also found an association 345 
between miR-1254 and clinical outcome. Other existing data on miR-1254 are limited; of 346 
note is that Tijsen et al demonstrated upregulation of miR-1254 in HF cases compared to 347 
healthy controls.5 An association between higher baseline miR423-5p levels and signs of 348 
progressive HF has been demonstrated in animal models,6 and human studies with limited 349 
sample size.3,5 Rising miR423-5p has also been related to worsening left ventricular function 350 
and has been shown to be upregulated in non-ST elevation myocardial infarction patients.23 351 
Our results agree with the findings of the aforementioned studies. Conversely, in recent a 352 
study in 236 acute HF patients, an inverse association was observed between miR423-5p 353 
and hospital readmission.8 However, this finding could not be reproduced in the validation 354 
cohort which was examined.8 Smaller studies have previously demonstrated higher 355 
circulating levels of miR-320a in HF patients compared to healthy individuals.7,24 In addition, 356 
rat models have proven that overexpression of miR-320a leads to a greater loss of 357 
cardiomyocytes during infarction and that inhibition of miR-320a leads to reduced infarction 358 
size.25 Furthermore, miR-320a showed a protective effect on left ventricular remodeling after 359 
myocardial ischemia-reperfusion injury in a rat model.26 The results of the current study are 360 
in line with these previous studies, and further expand the evidence concerning miR-320a by 361 
showing that baseline measurements are independently associated with adverse prognosis 362 
in patients with HF, and that repetitively-measured miR-320a is independently associated 363 
with heart failure hospitalization in particular. The temporal pattern of miR-378a-3p was also 364 
associated with the primary endpoint. Naga Prasad et al showed downregulation of miR-365 
378a-3p in left ventricular free wall tissue of HF patients with dilated cardiomyopathy.4 In 366 
contrast, in the current study we examined circulating levels of miR-378a-3p. In addition, 367 
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Weber et al found higher levels of circulating miR-378a-3p in 5 patients with coronary artery 368 
disease, compared to 5 healthy controls.27 However, studies other than ours on the 369 
prognostic value of miR-378a-3p in patients with HF are lacking.  370 
Repeatedly measured, highly-abundant miRs only showed age-and sex-adjusted 371 
significant associations with the primary endpoint, and associations disappeared after 372 
multivariable adjustment. Possibly, prognostic information of these circmiRs, which are 373 
probably not produced by the heart, can be easily diluted.  Conversely, myomiRs, i.e. miRs 374 
which are skeletal- and cardiac-muscle specific, carry potential to provide prognostic 375 
information that is incremental to clinical characteristics. Such myomiRs play a central role in 376 
myogenesis regulation and muscle remodeling.28,29 Although the main sources of circulating 377 
myomiRs, and in particular the relationship between myomiRs in tissue and plasma have yet 378 
to be fully elucidated, an association between cardiac damage (caused by myocardial 379 
infarction or  myocarditis) and upregulation of circulating myomiRs  has been previously 380 
demonstrated.15 Moreover, circulating myomiR levels have been associated with skeletal 381 
muscle wasting.30 We examined several myomiRs in the current investigation (miR133a-3p, 382 
miR133b, miR208a-3p and miR499a-5p). However, myomiRs are lowly expressed in the 383 
circulation, as illustrated by the fact that they were non-detectable in a large proportion of the 384 
samples available in our study. Thus, we were forced to perform a simplified analysis and 385 
examined the association between presence of detectable myomiR levels at baseline and 386 
occurrence adverse events. The loss of information inherent to such an analysis may have 387 
obscured potential associations with the outcome. Therefore, more sensitive assays are 388 
needed to properly examine the roles of myomiRs in HF.  389 
To remove noise by less robust QPCR results we designed and implemented a strict 390 
and conservative algorithm to remove unreliable QPCR data, and at the same time retain 391 
reliable assessment of ‘too low to detect’ signals.  Furthermore, we used miR486-5p to 392 
normalize our data, as using such endogenous miRs for this purpose has been shown to 393 
carry advantages.17 We have separately described our quality control algorithm we used 394 
here (provided for review purposes) and given the strong concordance between three large 395 
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cohorts we have thus measured strengthens the point of view that such algorithms help to 396 
remove noise and improve reproducibility.  397 
Some aspects of this study warrant consideration. First, aortic banding has been 398 
used to model heart failure. This is a model that shows strong similarity to the TAC model in 399 
mice and has previously been used in multiple studies as a model for pressure-overload 400 
hypertrophy.31-34 This model may not be fully representative of human left ventricular 401 
dysfunction. However, our observation that miR 1306-5p, identified in our swine model, does 402 
provide prognostic potential in the clinic, underscores the validity of our approach. Second, 403 
we did not adjust our analyses for multiple comparisons, because the miRs we examined 404 
were not selected in a hypothesis-free manner but had resulted from previous fundamental 405 
and clinical studies. Nevertheless, if we applied Bonferroni correction, the results would 406 
remain statistically significant. The association between repeated miR1306-5p and the 407 
primary endpoint rendered a HR(95%CI) of 4.69(2.18–10.06) and a p-value < 0.0001; since 408 
we examined 7 repeatedly measured miRs, the Bonferroni threshold for the p-value would 409 
be 0.05/7=0.007. Furthermore, we focused on patients with known heart failure. Studies 410 
using a healthy control group may provide insights into temporal miR patterns in healthy 411 
persons. 412 
In conclusion, in patients hospitalized for AHF, baseline and repeatedly-assessed 413 
miR-1306-5p was independently associated with adverse clinical outcome. Associations of 414 
temporal patterns of miR-320a, miR-378a-5p, miR-423-5p and miR-1254 with adverse 415 
clinical outcome were not independent of clinical characteristics. Myocyte-specific miRs were 416 
non-detectable in a large proportion of the samples. More sensitive myomiR assays are 417 
needed in order to precisely estimate the risk associated with elevated levels of miRs such 418 
as miR1306-5p, and to investigate whether cardiac specific myomiRs on their part are 419 
capable of providing additional information to established, clinical risk predictors.  420 
421 
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Figure titles and legends 556 
 557 
Figure 1: Trans-coronary gradients in plasma microRNAs. 558 
The number indicates the number of pigs (out of a total of 44 pigs) with both a detectable 559 
venous and arterial microRNA value. The gradient is calculated as arterial minus venous Ct 560 
value of the microRNA, and shown as Mean±SEM. A negative value indicates release of the 561 
microRNA by the myocardium, and a positive value indicates uptake. The p-value is 562 
calculated using a paired samples T-test, and indicates the difference between arterial and 563 
venous Ct value of the microRNA. 564 
 565 
Figure 2: Kaplan-Meier survival curves for the primary endpoint of death or readmission for 566 
HF in the four quartiles of baseline miR-1306-5p levels. 567 
Q1 lowest quartile, Q4 highest quartile. 568 
A large section of the discussion is based on the consistency between the results of this study 
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the data from Bayes-Genis et al, Ms. No.: EURJHF-17-436-MDR in the current manuscript. 
Please see also the added email sent by Dr. Bayes-Genis, which was added for review only, in 
which he provides written permission to use the data from Bayes-Genis et al, Ms. No.: 
EURJHF-17-436-MDR. We also added cover letter of the Bayes-Genis manuscript, Ms. No.: 
EURJHF-17-436-MDR, for review purposes only.  
 Furthermore, the manuscript by Bayes-Genis et al, Ms. No.: EURJHF-17-436-MDR, has 
been resubmitted at the same time as this manuscript, and both manuscripts are currently in 
the same stage of the review process.  
 
Ref. 21 needs to be updated 
Response: As requested, we have updated Ref. 21. 
 
Response to Reviewer
Reviewers' comments: 
 
Reviewer #1: I would like to thank the authors for their very considered responses to the points I 
made at the first review. I agree that consideration of total or recurrent events is not necessary. 
Otherwise, I think that their responses are very appropriate. 
Response: We thank the reviewer for the constructive comments which have improved the 
paper. 
 
Reviewer #2: The authors have replied correctly to my comments. The fact that miR-1306-5p does 
not add to NT-proBNP, the benchmark prognostic marker in HF, in terms of discrimination 
(reclassification), must be clearly indicated in the abstract and in the discussion. 
Response: As requested by the reviewer, we have indicated the fact that miR-1306-5p does not 
add to NT-proBNP, in terms of discrimination, in the abstract and in the discussion: 
Abstract, lines 46-47:- Baseline miR-1306-5p did not improve model 
discrimination/reclassification significantly compared to NT-proBNP. 
Abstract, lines 51-53: “Repeatedly-measured miR-1306-5p was positively associated 
with adverse clinical outcome in AHF, even after multivariable adjustment including NT-
proBNP. Yet, baseline miR-1306-5p did not add significant discriminatory value to NT-proBNP.” 
 Discussion, lines 312-314: “This association was independent of NT-proBNP. However, 
a model containing baseline miR-1306-5p measurements did not significantly improve model 
discrimination or reclassification when compared to NT-proBNP. “ 
 
Reviewer #3:  I congratulate the authors. The answers are adequately answered. 
Response: We thank the reviewer for the suggestions that have indeed improved the paper. 
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Table 1 – Differentially expressed microRNAs across tissue samples 
MiR Fold change* Adjusted p-value 
306-5p 1,354 0.002 
132 1,554 0.013 
133a-3p 1,107 0.004 
142-5p 1,992 <0.001 
144 1,457 0.004 
144-5p 2,621 <0.001 
150 1,767 0.006 
15b 1,996 <0.001 
15b-5p 1,922 <0.001 
342 1,932 <0.001 
365-3p 1,507 <0.001 
451 3,015 <0.001 
532-3p 1,956 0.001 
7139-3p 1,889 <0.001 
92b-3p 1,04 0.015 
99b-3p -1,225 0.023 
133b 0,69 0,07 
103 -0,198 0,72 
143-3p -0,251 0,75 
143-5p -0,297 0,755 
28-3p -0,347 0,53 
486-5p 0,166 0,77 
7f 0,472 0,51 
99 -0,53 0,11 
Myocardial samples were obtained from the left ventricular free wall and compared between sham-operated and TAC-treated 
swine. P-values were calculated using the negative binomial model from DESeq. MiR = microRNA.  
* Log2 fold change 
Table 1
Table 2 – Baseline characteristics  
 
Variables Overall sample (n=475) 
Demographic characteristics, median [IQR] or number (%)  
Age, years 73 [64 - 80] 
Female, % 36.6 (167) 
Caucasian,  % 94.3 (430) 
Measurements at baseline, median [IQR] or number (%)  
Body mass index, kg/m2 27.5 [24.7 - 31.1] 
Systolic blood pressure, mmHg 125 [110 - 147] 
Diastolic blood pressure, mmHg 75 [65 - 85] 
Heart rate, bpm 85 [72 - 100] 
eGFR 46 [34.4 - 61.7] 
Left ventricular ejection fraction, % 30 [21 - 42] 
Heart failure with reduced ejection fraction, % 79.8 (289) 
NT-proBNP (pg/ml) 4143.7 [2097.5 - 9053.2] 
Medical history, number (%)  
Previous heart failure admission within 6 months 19.8 (90) 
Ischemic heart failure 48.1 (219) 
Myocardial infarction 40.4 (184) 
Hypertension 50 (228) 
Atrial fibrillation 42.5 (194) 
Diabetes Mellitus 36.5 (166) 
Stroke 17.5 (80) 
 
IQR = Inter-quartile range, eGFR = estimated glomerular filtration rate. 
 
Table 2
